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Epidermal  growth  factor  receptor  (EGFR)  mutation  is  one  of  the  hallmarks  of  cancer 
progression  and  resistance  to  anticancer  therapies,  particularly  non-small  cell  lung 
carcinomas  (NSCLCs).  In  contrast  to  the  canonical  EGFR  activation  in  which  tyrosine 
residues are engaged, we have demonstrated that the non-canonical pathway is triggered by 
phosphorylation of serine and threonine residues through p38 and ERK MAPKs, respectively. 
The  purpose  of  this  study is  to  investigate  the  role  of  non-canonical  EGFR pathway in 
resistance mechanism against cisplatin treatment. Wild type and mutated (exon 19 deletion) 
EGFR-expressing cells responded similarly to cisplatin by showing MAPK-mediated EGFR 
phosphorylation. It is interesting that internalization mechanism of EGFR was switched from 
tyrosine kinasedependent to p38-dependent fashions, which is involved in a survival pathway 
that counteracts cisplatin treatment. We therefore introduce a potential combinatorial therapy 
composed of p38 inhibition and cisplatin to block the activation of EGFR, therefore inducing 
cancer cell death and apoptosis.
